Gary Sinclair, MD
Internal Medicine · Dallas, TXNPI 1891757613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $476,359 of the $599,098 with a category attached, or 79.5%. 21 manufacturers reported payments, led by Viiv Healthcare Company at 50.0% of the total. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,165 payments — averaging $514.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$300K
- Janssen Products, LP$210K
- Merck$51K
- Theratechnologies Inc.$28K
- Gilead$7K
- Johnson & Johnson$2K
- plus $1K from 15 others
Across 417 payments — averaging $6727.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$997K
- Viiv Healthcare Company$683K
- Merck$517K
- Roche Molecular Systems, Inc.$277K
- AbbVie$218K
- Janssen Research & Development, LLC$59K
- plus $55K from 2 others
What the payments were for
- Consulting fees$24,2114%
- Speaking & faculty fees$476,35980%
- Travel & lodging$69,71812%
- Food & beverage$27,3885%
- Education$1,4210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 448 | $299,558 |
| Janssen Products, LP | 221 | $209,762 |
| Merck | 165 | $51,428 |
| Theratechnologies Inc. | 60 | $27,993 |
| Gilead | 92 | $7,025 |
| Johnson & Johnson(2 entities) | 123 | $2,040 |
| EMD Serono, Inc. | 10 | $225 |
| Novo Nordisk | 13 | $217 |
| Napo Pharmaceuticals Inc | 9 | $166 |
| Dynavax Technologies Corporation | 1 | $120 |
| Janssen Scientific Affairs, LLC | 2 | $114 |
| GSK | 2 | $87 |
| AbbVie | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Pfizer | 2 | $51 |
| Verity Pharmaceuticals Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Lilly USA, LLC | 1 | $13 |
| Romark Laboratories, LC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$599,098 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 292 | $1,303,974 |
| DovatoDolutegravir Sodium/Lamivudine | 134 | $387,574 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 107 | $384,443 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 104 | $383,293 |
| TivicayDolutegravir Sodium | 136 | $327,875 |
| RukobiaFostemsavir Tromethamine | 25 | $222,545 |
| DescovyEmtricitabine/Tenofov Alafenam | 107 | $221,786 |
| PrezcobixDarunavir/Cobicistat | 95 | $220,284 |
| PifeltroDoravirine | 74 | $130,880 |
| CabenuvaCabotegravir/Rilpivirine | 19 | $104,337 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 24 | $80,382 |
| Egrifta SvTesamorelin Acetate | 11 | $73,971 |
| IsentressRaltegravir Potassium | 23 | $43,274 |
| EliquisApixaban | 64 | $40,009 |
| TrulicityDulaglutide | 32 | $30,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay, Rukobia, Cabenuva | $299,558 | $1,426,774421 claims |
| Janssen Products, LPSymtuza | $209,762 | $1,303,974292 claims |
| GileadBiktarvy, Descovy, Genvoya, Vemlidy | $7,025 | $700,675247 claims |
| Johnson & JohnsonPrezcobix | $2,040 | $220,28495 claims |
| MerckPifeltro, Isentress, Januvia | $51,428 | $187,639113 claims |
| Theratechnologies Inc.Egrifta Sv | $27,993 | $73,97111 claims |
| PfizerEliquis | $51 | $40,00964 claims |
| Lilly USA, LLCTrulicity | $13 | $30,74032 claims |
| Janssen Scientific Affairs, LLCEdurant | $114 | $16,24911 claims |
| GSKAnoro Ellipta | $87 | $9,77720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
- Hussein TawbiHouston$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.